Hydrolysis breaks the peptide bonds themselves, fragmenting the molecule into smaller, inactive pieces
Chronic Weight Management: In June 2021, the FDA approved semaglutide (Wegovy) at a higher dose of 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia
Fatigue is almost always listed as a potential side effect of semaglutide, and 5-6% of people on semaglutide experience exhaustion or fatigue due to this drug
Wegovy HD delivered 20.7% mean weight loss over 72 weeks in the STEP UP trial
The effectiveness of OZEMPIC tablets (1.5 mg, 4 mg and 9 mg strengths) [see Dosage and Administration (2.2)] and RYBELSUS (3 mg, 7, mg and 14 mg strengths) [see Dosage and Administration (2.3)] has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus [see Clinical Pharmacology (12.3)]
